To further confirm the potential of serum MASP2 as a biomarker of lupus, we conducted a validation cohort that included 100 SLE patients, 100 RA patients, 100 OA patients, 100 gout patients, 44 SS patients and 41 AS patients. This evidence concerns the gene MASP2 and rheumatoid arthritis.